Device revision or removal

In the sacral neuromodulation group, 3% of women (6 of 189) had their device revised or removed during the 6-month period.

Effect: adverse; 3% (6 of 189 women)

In the sacral neuromodulation group, 3% of women (6 of 189) had their device revised or removed during the 6-month period.

Effect: adverse; 3% (6 of 189 women)

In the sacral neuromodulation group, 3% of women (6 of 189) had their device revised or removed during the 6-month period.

Effect: adverse; 3% (6 of 189 women)

In the sacral neuromodulation group, 3% of women (6 of 189) had their device revised or removed during the 6-month period.

Effect: adverse; 3% (6 of 189 women)

In the sacral neuromodulation group, 3% of women (6 of 189) had their device revised or removed during the 6-month period.

Effect: adverse; 3% (6 of 189 women)

In the sacral neuromodulation group, 3% of women (6 of 189) had their device revised or removed during the 6-month period.

Effect: adverse; 3% (6 of 189 women)

In the sacral neuromodulation group, 3% of women (6 of 189) had their device revised or removed during the 6-month period.

Effect: adverse; 3% (6 of 189 women)

In the sacral neuromodulation group, 3% of women (6 of 189) had their device revised or removed during the 6-month period.

Effect: adverse; 3% (6 of 189 women)

In the sacral neuromodulation group, 3% of women (6 of 189) had their device revised or removed during the 6-month period.

Effect: adverse; 3% (6 of 189 women)

In the sacral neuromodulation group, 3% of women (6 of 189) had their device revised or removed during the 6-month period.

Effect: adverse; 3% (6 of 189 women)

In the sacral neuromodulation group, 3% of women (6 of 189) had their device revised or removed during the 6-month period.

Effect: adverse; 3% (6 of 189 women)

In the sacral neuromodulation group, 3% of women (6 of 189) had their device revised or removed during the 6-month period.

Effect: adverse; 3% (6 of 189 women)

In the sacral neuromodulation group, 3% of women (6 of 189) had their device revised or removed during the 6-month period.

Effect: adverse; 3% (6 of 189 women)

In the sacral neuromodulation group, 3% of women (6 of 189) had their device revised or removed during the 6-month period.

Effect: adverse; 3% (6 of 189 women)

In the sacral neuromodulation group, 3% of women (6 of 189) had their device revised or removed during the 6-month period.

Effect: adverse; 3% (6 of 189 women)

In the sacral neuromodulation group, 3% of women (6 of 189) had their device revised or removed during the 6-month period.

Effect: adverse; 3% (6 of 189 women)

In the sacral neuromodulation group, 3% of women (6 of 189) had their device revised or removed during the 6-month period.

Effect: adverse; 3% (6 of 189 women)

In the sacral neuromodulation group, 3% of women (6 of 189) had their device revised or removed during the 6-month period.

Effect: adverse; 3% (6 of 189 women)

In the sacral neuromodulation group, 3% of women (6 of 189) had their device revised or removed during the 6-month period.

Effect: adverse; 3% (6 of 189 women)

In the sacral neuromodulation group, 3% of women (6 of 189) had their device revised or removed during the 6-month period.

Effect: adverse; 3% (6 of 189 women)

In the sacral neuromodulation group, 3% of women (6 of 189) had their device revised or removed during the 6-month period.

Effect: adverse; 3% (6 of 189 women)

In the sacral neuromodulation group, 3% of women (6 of 189) had their device revised or removed during the 6-month period.

Effect: adverse; 3% (6 of 189 women)

In the sacral neuromodulation group, 3% of women (6 of 189) had their device revised or removed during the 6-month period.

Effect: adverse; 3% (6 of 189 women)

In the sacral neuromodulation group, 3% of women (6 of 189) had their device revised or removed during the 6-month period.

Effect: adverse; 3% (6 of 189 women)

In the sacral neuromodulation group, 3% of women (6 of 189) had their device revised or removed during the 6-month period.

Effect: adverse; 3% (6 of 189 women)

In the sacral neuromodulation group, 3% of women (6 of 189) had their device revised or removed during the 6-month period.

Effect: adverse; 3% (6 of 189 women)

In the sacral neuromodulation group, 3% of women (6 of 189) had their device revised or removed during the 6-month period.

Effect: adverse; 3% (6 of 189 women)